Ranked among the 5,000 newest matching findings; add words or filters to narrow the search.
Mycophenolate mofetil showed no clear difference in dialysis compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in relapse at any time point compared with cyclophosphamide (low certainty).
Mycophenolate mofetil probably leads to higher remission at 6 months compared with cyclophosphamide (moderate certainty).
Mycophenolate mofetil may leads to higher serious adverse events compared with cyclophosphamide (low certainty).
Mycophenolate mofetil showed no clear difference in infection compared with cyclophosphamide (moderate certainty).
Intravenous immunoglobulin showed no clear difference in death compared with placebo (low certainty).
The intervention may leads to lower dialysis at one year (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Intravenous immunoglobulin may leads to higher response at 3 months compared with placebo (low certainty).
Intravenous immunoglobulin showed no clear difference in relapse at 3 months compared with placebo (low certainty).
Intravenous immunoglobulin may leads to higher adverse events compared with placebo (low certainty).
The review found no eligible studies for this question.
The intervention may leads to higher sustained remission (low certainty).
The review found no eligible studies for this question.
The intervention showed no clear difference in total number of adverse events (low certainty).
The intervention may leads to higher serious infections (low certainty).
Pulse cyclophosphamide showed no clear difference in death at final compared with continuous cyclophosphamide (low certainty).
Mohs micrographic surgery showed no clear difference in recurrence at 3 years compared with surgical excision (low certainty).